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EXAMINING THE POTENTIAL OF ANTI-A(BETA) ANTIBODIES 
AS ALZHEIMER’S THERAPEUTICS 
SEAN PHAM 
ABSTRACT 
 Alzheimer’s disease results from an accumulation of aggregated amyloid beta 
peptide into oligomeric forms.  Soluble oligomers are neurotoxic species, which are 
believed to be the pathophysiological cause of Alzheimer’s neurodegeneration.  Amyloid 
β species (Aβ) are formed via normal physiological cleavage of amyloid precursor 
protein by β and γ secretases.  Cleaved isoforms aggregate further to form oligomeric 
configurations of Αβ peptide.  To target toxic soluble Aβ oligomers, monoclonal 
antibodies have been synthesized.  Experimental analysis demonstrates the ability of 
these antibodies to recognize synthetic and endogenous oligomers.  In transgenic mice 
designed to overexpress oligomeric isoforms of Aβ, the antibodies were able to reduce 
the cerebral amyloid load with proceeding improvements in cognitive abilities.  However, 
large-scale clinical trials corroborated results indicating diminished amyloid load, but 
failed to produce observable improvements in clinical outcome in patients with 
Alzheimer’s disease.  Simply put, the removal of amyloidogenic species was insufficient 
in alleviating the associated neurodegeneration and elicited no improvement in cognitive 
ability, suggesting that Aβ might not be the responsible pathogen in Alzheimer’s.  The 
successes of antibodies in in vitro and transgenic mice studies suggest the potential of 
antibodies in the treatment of Alzheimer’s, but the inability of these drugs to produce 
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marked improvements in clinical trials questions the role of amyloid in the 
pathophysiology of the disease.  
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INTRODUCTION 
In 1906, Alois Alzheimer presented his observations of a 51 year-old female patient, 
Auguste D., who exhibited signs of rapid memory loss and cognitive deterioration 
consequent to her death four and half years later (Small & Cappai, 2006).  Upon post-
mortem examination, the brain was shown to have atrophied with unique neurofibrillary 
tangles and deposits (Small & Cappai, 2006).  The extracellular deposits of what we now 
know to be amyloid beta protein (Aβ) are characteristic of the neurodegenerative disease 
named for Alzheimer, and are processed via endogenously present proteolytic processing 
cascades (Shoji et al. 1992).  The protein is produced from a precursor known as amyloid 
precursor protein (APP), which is cleaved proteolytically via endosomal lysosomes to 
produce C-terminal and N-terminal fragments (Shoji et al. 1992).   
Initial cleavage of APP is carried out by either α or β-secretase, and their enzymatic 
products can undergo secondary cleavage by γ-secretase to produce p3 peptide and Αβ, 
respectively (Ling et al. 2003).  The two major forms of Αβ, Αβ40 and Αβ42, are 
normal endogenous products of proteolysis via secretases – they can be detected in the 
cerebrospinal fluid (CSF), along with various C-terminal fragments (CTF), of both 
individuals with Alzheimer’s and those without (Ling et al. 2003, Selkoe, 1994).  In 
short, the pathophysiology of Alzheimer’s originates from normal proteolytic cleavage to 
produce potentially pathogenic Αβ species.   
 Though controversial, the amyloid hypothesis of Alzheimer’s has guided modern 
research and therapeutic development.  Current results suggest that the neurotoxicity and 
cognitive impairment associated with Alzheimer’s originates from the accumulation of 
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Αβ into soluble oligomers.  In vitro accumulation of Αβ species into oligomeric forms 
implicates the Αβ42 isoforms as the predominant component of toxic neurodegenerative 
oligomers (El-Agnaf et al. 2000).  The 42 amino acid long Αβ peptide aggregates more 
rapidly when compared to Αβ40, and its administration to cells in culture exhibits lower 
cell viability (El-Agnaf et al. 2000).  The results of in vitro comparisons of Αβ isoforms 
point to Αβ42 as the pathogenic species of Alzheimer’s.  
Research has pointed to soluble oligomeric intermediates of Αβ as the toxic species 
responsible for the cognitive symptoms of Alzheimer’s, which can be recognized using 
monoclonal antibodies designed (Kayed et al. 2003).  Antibodies to Αβ are designed by 
vaccinating rabbits with a molecular mimic of the soluble oligomers (Kayed et al. 2003).  
The rabbit immune response produces anti-amyloid antibodies, which are then collected 
and isolated from polyclonal serum (Kayed et al. 2003).  Studies with the antibodies in 
neuroblastoma cell lines demonstrate that the antibodies can mediate the neurotoxicity 
associated with soluble Αβ oligomers, results that have been corroborated by other 
research (Kayed et al. 2003).  The ability of oligomer-specific antibodies to selectively 
recognize and neutralize the neurotoxicity of pathological species implicated in 
Alzheimer’s makes them a promising avenue for new Alzheimer’s therapeutics.  This 
thesis will review the literature available to highlight the current uses of antibodies in 
research and clinical studies to demonstrate their potential as new treatment options for 
Alzheimer’s disease.   
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PUBLISHED STUDIES 
 
Source material was obtained using PubMed and Google Scholar.  Articles regarding 
the currently available treatment options for Alzheimer’s were found using the keywords 
“treatments” and “Alzheimer’s disease.”  Individual therapeutics were then cross 
referenced with “Alzheimer’s disease” to gather more information on each drug.  The 
research uses of monoclonal antibodies were found using key terms “antibodies”, 
“amyloid”, “Αβ”, and “Alzheimer’s disease.”  Transgenic mice trials were located by 
adding the keyword “transgenic” to the previously mentioned terms.  The key term 
“immunotherapy” was added to the aforementioned terms along with “clinical” to 
identify the application of antibodies in clinical trials.   
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POTENTIAL OF ANTI-Aβ ANTIBODIES AS ALZHEIMER’S THERAPEUTICS  
Treatment of Alzheimer’s disease  
Current therapeutics to treat Alzheimer’s attempt to delay the associated cognitive 
degeneration – treatment is directed toward slowing the progression of the disease rather 
than reversing or curing.  The two lines of treatment for remedying memory loss and 
dementia are acetylcholinesterase inhibitors and memantine.  
The cognitive decline associated with Alzheimer’s is a result of the neuronal 
degeneration.  Experimental analysis in mice with the disease demonstrated reduced 
labeling with tritiated acetylcholine, representing a loss of cholinergic binding sites in the 
pathological state (Whitehouse et al. 1985).  Radioactively labeled nicotine discriminates 
the preferential loss of nicotinic receptors over muscarinic (Whitehouse et al. 1985).  
Label studies in transgenic mice also elucidated the region of mass neuronal degeneration 
as the nucleus basalis; thus as the nucleus degrades in the pathological state, the number 
cholinergic binding sites decreases (Whitehouse et al. 1985).  Subsequent 
immunoreactivity analyses of diseased brain tissue from the frontal cortex confirm the 
loss of nicotinic acetylcholine receptors due to Alzheimer’s (Schroder et al. 1991).  
Comparison of immunoprecipitate with Nissl stain demonstrates that the pathology 
causes a decreased expression of nicotinic cholinergic binding sites rather than simply a 
loss of chemoreactivity (Schroder et al. 1991).   
In addition to the loss of nicotinic binding sites, Alzheimer’s reduces 
neurotransmission by decreasing the activity of choline acetyltransferase.  The absence of 
this enzyme diminishes the synthesis and availability of neurotransmitter acetylcholine 
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for cognitive activity (Kellar et al. 1985).  Post-mortem examinations of individuals 
suffering from Alzheimer’s and dementia demonstrate a deficiency of choline 
acetyltransferase, primarily in the temporal lobe (Wilcock et al. 1982).  The enzyme 
deficit is correlated to the increase of neuritic plaques as well as the increase in severity 
of dementia (Wilcock et al. 1982).  As activity of choline acetyltransferase declines, 
memory and cognition steadily degenerate consequently (Wilcock et al. 1982).   
Because of the cholinergic basis of the Alzheimer’s pathology, it follows that 
treatment of the associated cognitive symptoms would target increasing 
neurotransmission via acetylcholine.  By administering acetylcholinesterase inhibitors in 
treating Alzheimer’s, the aim is to raise levels of acetylcholine to sustain cognitive ability 
and alleviate symptoms.  However, drugs of this type inhibit peripheral cholinesterase, 
causing intolerable gastrointestinal and hepatotoxic side effects (Rogers et al. 1998).  To 
improve efficacy along with safety and tolerability, the selectivity of cholinesterase 
inhibitors must be addressed.  Preclinical testing with donepezil demonstrated improved 
selectively for acetylcholinesterase over butyrylcholinesterase, and in clinical studies, 
exhibited positive cognition effects and good tolerability when compared with placebo 
(Rogers et al. 1998).  Another acetylcholinesterase inhibitor, rivastigmine, produces 
synaptic effects by competitively binding with the enzyme directly.  Rivastigmine is 
hydrolyzed similarly to acetylcholine, but its carbamoyl moiety remains bound to 
enzyme, preventing it from further degradation (Polinsky, 1998). Unlike donepezil, 
rivastigmine inhibits acetylcholinesterase and butyrylcholinesterase; the latter has been 
implicated in the severity of dementia (Farlow et al. 2000).  Clinical studies demonstrate 
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rivastigmine’s ability to delay cognitive and mental decline, displaying side effects 
related to peripheral inhibition, similar to those of other cholinesterase inhibitors (Farlow 
et al. 2000).   
	
Figure 1: Compared to placebo, rivastigmine delays cognitive decline and improves 
mental health over an extended period.  Additionally, administration of rivastigmine in 
the placebo group after 26 weeks produced marked improvements (Farlow et al. 2000). 
In addition to the effects on synaptic transmission, acetylcholinesterase inhibitors 
seem to have neuroprotective effects on the Alzheimer’s brain.  Studies with human 
neuroblastoma cell cultures demonstrate the protective properties of three different 
inhibitors commercially available for treatment of Alzheimer’s: donepezil, rivastigmine, 
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and galantamine.  Pretreatment of cell lineages with these drugs offers protection against 
neuronal death induced by okadaic acid (Arias et al. 2005).  By mediating Aβ toxicity, 
the drugs can also confer a degree of anti-apoptotic effects to further mediate the extent 
of cell death (Arias et al. 2005).  The neuroprotective benefits of cholinesterase inhibitors 
are impeded with the administration of antagonists of nicotinic acetylcholine receptors, 
suggesting that neuroprotection is imparted by the receptors (Arias et al. 2005).  
Blockades of the receptors at high concentrations of drug create U-shaped curves of 
efficacy, in which maximal levels of protection are achieved at intermediate 
concentrations (Arias et al. 2005).   
	
Figure 2: Comparison of the optimal concentrations of acetylcholinesterase inhibitors, 
galantamine, donepezil, and rivastigmine, for neutralizing neurotoxicity induced by 
okadaic acid administration (Arias et al. 2005). 
A downstream effect of Αβ oligomers is the over-excitation of NMDA receptors, 
which are crucial components for long-term potentiation and long-term memory (De 
	8 
Felice et al. 2007).  This over stimulation effect produces reactive oxidative species that 
interfere in synaptic transmission, long-term potentiation, and plasticity exhibitory in 
Alzheimer’s (De Felice et al. 2007).  The production of neurodegenerative reactive 
oxidative species via amyloid derived diffusible ligands (ADDLs) can be blocked by 
memantine (De Felice et al. 2007).  Specifically, memantine blocks Ca2+ influx caused by 
ADDL binding to the NMDA receptor, and by doing so, memantine inhibits 
mitochondrial production of superoxides and peroxides (De Felice et al. 2007).  Because 
of its ability to mediate elevated levels of reactive oxidative species, memantine is an 
effective therapeutic in delaying the onset of cognitive decay.   
In phase III clinical trials, subjects on memantine exhibited significant improvements 
in cognition when compared to placebo controls (Winblad et al. 2007).  Safety and 
tolerability were similar amongst the two groups, with the incidence of minor adverse 
events marginally higher for the memantine group (Winblad et al. 2007).  Patients with 
moderate to severe progressions of Alzheimer’s were able to recover mechanical 
capabilities, such as independent bathing and dressing, as well as improve behavioral 
aspects (Reisberg et al. 2003).  Treatment with memantine relieves distress on both 
patient and caretaker by mediating burdens associated with later stages of Alzheimer’s 
(Reisberg et al. 2003). 
In combination therapy with acetylcholinesterase inhibitors, memantine demonstrates 
significant improvement in cognitive ability when compared to treatment with 
cholinesterase inhibitors alone.  Administration of memantine to patients with mild to 
moderate Alzheimer’s who were already on stable treatment with the cholinesterase 
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inhibitor donepezil elicited observable improvements in behavior and memory without 
discernible differences in incidence of adverse events (Tariot et al. 2004).  Six areas of 
cognitive abilities as well as functionality in everyday tasks exhibited improvement in the 
memantine group (Tariot et al. 2004).  Individuals in the memantine group remained 
more steadily above baseline whereas the placebo group observed steady declines in 
cognition (Tariot et al. 2004).  Additionally, the memantine exhibits decreased frequency 
of mental disturbance and psychiatric symptoms (Tariot et al. 2004).  
However, as efficacious as current therapeutics may be, they are directed solely 
toward delaying the onset of inevitable cognitive degeneration.  More research is required 
in order to discover suitable treatment options to reverse or cure the disease progression.   
Monoclonal Antibodies 
Monoclonal antibodies provide a hopeful avenue for the future of Alzheimer’s 
therapeutics.  Because of their unique specificity and manipulability, monoclonal 
antibodies can be used to precisely target pathological species and neutralize their 
toxicity.  They have been used universally in research, and their successes show promise 
for drug development.   
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The toxic species associated with Alzheimer’s, Aβ peptide, can be recognized using 
monoclonal antibodies.  By exposing rabbits to synthetic forms of Αβ peptide, antibodies 
against amyloid can be produced endogenously (Solomon et al. 1996).  When anti-
amyloid antibody is introduced to fibrillar conformations of Αβ, the aggregated forms of 
Figure 3: NAB61 specifically stains 
oligomeric forms of amyloid as seen in 
immunohistochemical studies (Lee et 
al. 2006). 
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revert back to an amorphous state (Solomon et al. 1996).  The ability to prevent the in 
vitro aggregation of amyloid, implicated in the pathogenesis of Alzheimer’s, present 
potential for the development of such antibodies as therapeutics (Solomon et al. 1996).    
Monoclonal antibody, NAB61, was designed to recognize oligomeric forms of the 
Αβ peptide (Lee et al. 2006).  Immunoreactivity and specificity of the antibody was 
assessed using ELISA and synthetic Αβ aggregates, revealing its selectivity for amyloid 
oligomers over non-oligomer forms as well as its recognition of a conformation 
dependent N-terminus epitope (Lee at el. 2006).  Immunohistochemical studies also 
confirm that NAB61 recognizes amyloid plaques in diseased brain samples (Lee et al. 
2006).  In studies of different brain regions, NAB61 demonstrates regional selectivity for 
plaques in the mid-frontal cortex (Lee et al. 2006).  The pathology of Alzheimer’s 
originates in association cortices with increasing densities and aggregations of amyloid as 
the disease progresses; the localization of NAB61 onto oligomeric forms of Αβ in the 
Figure 4: NAB61 displays regional selectivity 
for amyloid in the mid-frontal cortex (Lee et al. 
2006). 
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mid-frontal cortex suggests that the antibody recognizes mature forms of amyloid peptide 
(Lee et al. 2006).  When administered to transgenic mice, NAB61 elicited improvements 
in spatial reference memory as tested using underwater mazes – the performance of 
antibody-treated transgenic mice was comparable to that of non-transgenic mice and 
significantly better than IgG-treated transgenic control mice (Lee et al. 2006).  However, 
assessment of levels of amyloid plaques and amyloid precursor protein in transgenic mice 
immunized with NAB61 demonstrated no significant difference in steady state levels 
between the antibody-treated transgenic mice and control groups (Lee et al. 2006).  The 
ability of NAB61 to improve cognition and memory does not affect amyloid 
pathogenesis, but relies on neutralizing the toxicity of existing amyloid oligomers (Lee et 
al. 2006).   
The application of antibodies in transgenic mice has elucidated that amyloid can be 
cleared using monoclonal antibodies in vivo via a Fc-independent mechanism (Bacskai et 
al. 2002).  To determine whether removing Aβ species by administration of antibodies 
can remediate amyloid associated neuritic dystrophy, transgenic mice where passively 
immunized with anti-amyloid antibodies (Brendza et al. 2005).  Brains were imaged in 
vivo using yellow fluorescent protein to monitor the number and area of dystrophic 
neurites over 72 hour and weeklong periods (Brendza et al. 2005).  Without treatment, 
there was no improvement in neuritic dystrophy; however, in the presence of antibody 
10D5, recovery of neuritic dystrophy following the clearance of amyloid deposits 
occurred as rapidly as 3 days (Brendza et al. 2005).  Comparison of 18 plaque deposits 
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from 7 different transgenic mice demonstrates consistent reduction in number and area 
dystrophic neurites as a result of the 10D5 treatment (Brendza et al. 2005).  
Soluble forms of amyloid have been implicated as the neurotoxic species responsible 
for the pathogenesis of Alzheimer’s (Kayed et al. 2003).  The effect of anti-Αβ-
protofibril antibodies in mediating the toxicity of soluble protofibrils was assessed in 
transgenic mice (Lord et al. 2009).  Transgenic mice were passively immunized with one 
of two antibodies, mAb1C3 and mAb158, which recognize linear and conformational 
epitopes of Αβ, respectively (Lord et al. 2009).  Because of its conformation dependent 
nature, mAb158 displays better selectivity to Αβ protofibrils (Lord et al. 2009).  
However, administration of either antibody elicited a neuro-protective effect, but the 
conformation dependent antibody, mAb158, does so at a lower concentration as a result 
of its selective binding to toxic soluble protofibrils (Lord et al. 2009).  Additionally, both 
antibodies prevent fibrillation of amyloid peptide in vitro (Lord et al. 2009).  The 
Figure 5: Treatment with anti-amyloid 10D5 reduces neuritic dystrophy 
within 3 days (Brendza et al. 2005). 
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antibodies both exhibited preventative properties, diminishing the aggregation of 
protofibrils and plaque formation in transgenic mice when compared to controls (Lord et 
al. 2009).   
In clinical trials, an increased level of serum anti-Aβ antibodies seems to be causal to 
decreased disease progression (Geylis et al. 2005).  To determine if commercial 
production of human antibodies would be viable for vaccines, cell lines were established 
to determine if human anti-Αβ antibodies could be synthesized in vitro (Geylis et al. 
2005).  The cell lines were produced from lymphocytes obtained from healthy blood 
samples, which were immortalized with Epstein-Barr virus and fused with mouse 
plasmacytoma cells to retain antibody specificity (Geylis et al. 2005).  Anti-Aβ 
Figure 6: Both antibodies impart equal levels of protection to the 
mice, but mAb158 reaches maximum protection at lower 
concentrations, demonstrating its selectivity (Lord et al. 2009). 
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antibodies were detected in the supernatant after centrifugation, with specificity to 
synthetic Αβ as determined by ELISA, specifically an N-terminus epitope of amyloid 
peptide (Geylis et al. 2005).  Immunohistochemcial analysis of synthesized antibody 
determined that the antibody does bind to endogenous amyloid in the Alzheimer’s brain 
(Geylis et al. 2005).  The success of human antibody synthesis via hybridoma 
manufacture promotes the development of anti-Αβ vaccination without the 
immunogenicity associated with murine or chimeric antibodies.   
Active and passive immunization has proved successful in eliminating toxic amyloid 
species in transgenic mice as well as in clinical trials; however, it has also elicited 
adverse events in human trials (Dodel et al. 2004).  In order to mediate the cognitive 
decay of Alzheimer’s while keeping side effects minimal, human immunoglobins 
containing anti-Aβ antibodies were administered to patients in clinical trial (Dodel et al. 
2004).  Five individuals suffering from Alzheimer’s disease were recruited for the study, 
and levels of Αβ cerebrospinal fluid and serum were measured over a 6-month period 
(Dodel et al. 2004).  Additional neuropsychological testing was conducted to track 
cognitive and behavioral progress (Dodel et al. 2004).  Over the test period, mean values 
of Αβ in CSF decreased 30.1% on average and increased from an average of 240.4 
pg/mL to 558.2 pg/mL in serum (Dodel et al. 2004).  Slight improvements in mental state 
were observed, but no cognitive decline was evident (Dodel et al. 2004).  There were no 
adverse effects associated with treatment (Dodel et al. 2004).  This early study of 
immunization with anti-Aβ antibody containing immunoglobins suggests that the 
treatment is well tolerated and could be promising in the existing line of therapy (Dodel 
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et al. 2004).   Bapineuzumab is a humanized monoclonal antibody targeted to the N-
terminus of Αβ peptide, specifically species deposited in plaques (Panza et al., 2010).  A 
phase 2 clinical trial of the proposed drug investigated its effect on cortical Aβ load as 
measured by 11-labeled Pittsburgh compound B (11C-PiB) radiotracer (Rinne et al., 
2010).  Over 78 weeks, 19 patients with mild to moderate Alzheimer’s were treated with 
bapineuzumab and compared against 7 patients given placebo (Rinne et al., 2010).  
Assessments of 11C-PiB levels indicated a mean decrease amongst the bapineuzumab 
group and mean increase within the placebo group, correlating to a reduction in cortical 
Aβ load due to administration of bapineuzumab (Rinne et al., 2010).  Adverse effects 
were reported to be mild to moderate in severity and short-lived, with the exception of 
incidence of vasogenic edema in 2 subjects, leading to their subsequent discontinuation 
(Rinne et al., 2010).   
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Figure 7: PET imaging of 11C-PiB demonstrates reduced cortical amyloid load following 
administration of bapineuzumab (A, B) compared to placebo (C, D) (Rinne et al. 2010). 
A phase 3 clinical trial of bapineuzumab assessed the ability of the antibody to 
change the clinical outcome of patients with mild to moderate Alzheimer’s, as well as 
discriminate between carriers and non-carriers of ApoE ε4 allele in regards to the 
incidence of vasogenic edema (Salloway et al., 2014).  The research team established 
groups based on presence of the ApoE ε4 allele, drug administered, bapineuzumab or 
placebo, and dosage (Salloway et al., 2014).  Cognitive ability and amyloid load were 
measured to determine disease progression and outcomes (Salloway et al., 2014).  
Increased incidences of vasogenic edema at increasing concentrations led to the 
discontinuation of the group receiving 2.0 mg/mL (Salloway et al., 2014).  Regardless of 
group classification, no significant differences in cognitive change from baseline were 
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observed (Salloway et al., 2014).  The PET assessment of 11C-PiB marker for cortical Αβ 
peptide determined that amongst carriers, there was a mean increase in standardized 
uptake value (SUVR) in the placebo group and no significant change over 71 weeks for 
the bapineuzumab group (Salloway et al., 2014).  Similarly, amongst non-carriers, there 
was no significant change in SUVR in the bapineuzumab, but no significant increase was 
observed in the placebo group (Salloway et al., 2014).  Measurements of phosphorylated 
tau in cerebrospinal fluid indicated significant reductions in the bapineuzumab group and 
significant increases in the placebo group for carriers (Salloway et al., 2014).  Amongst 
non-carriers, no group differences were observed in levels of phosphorylated tau 
(Salloway et al., 2014).  The incidence of adverse events were similar between carriers 
and non-carriers in both drug and placebo groups (Salloway et al., 2014).   Effusion or 
edema was the most prominent adverse event that arose as a result of bapineuzumab 
administration, consistent with increasing dosage and number of ApoE ε4 alleles 
(Salloway et al., 2014).  Incidence of neoplasm amongst 20 carriers and 23 non-carriers 
as a result of drug administration led to death (Salloway et al., 2014). 
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Figure 8: These graphs summarize the results for the phase 3 clinical trial, separating the 
results of carriers and non-carriers (Salloway et al., 2014). 
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 Clinical trials were conducted to assess the safety and pharmacological properties 
of anti-Aβ antibody, solanezumab, in patients with mild to moderate Alzheimer’s disease.  
The phase 2 trial involved 52 subjects taking either drug or placebo over a 12-week 
period (Farlow et al., 2012).  Magnetic resonance imaging (MRI) and samples of CSF 
were employed to track patient progress (Farlow et al., 2012).  Eight patients receiving 
solanezumab experienced 10 treatment emergent adverse events, two of which, subdural 
hematoma and lumbar puncture headaches, were attributed to the lumbar puncture 
required for CSF sampling (Farlow et al., 2012).  Imaging via MRI revealed no instances 
of vasogenic edema (Farlow et al., 2012).  Five patients experienced anti-solanezumab 
immunogenicity (Farlow et al., 2012).  Total concentrations of Aβ species increased in 
plasma for each of the dosing regiments, but increases were largest for the groups given 
100 mg weekly, 400 mg weekly, and 400 mg every 4 weeks (Farlow et al., 2012).  No 
significant differences in cognitive ability from baseline were observed between antibody 
and placebo groups (Farlow et al., 2012).  Solaneuzumab was deemed generally well 
tolerated with no incidence of adverse events consistent with other antibody trials, T-cell  
mediated inflammation and vasogenic edema (Farlow et al., 2012).  However, 
pharmacokinetic and pharmacodynamics assessment determined that the antibodies did 
not seem to neutralize amyloid toxicity, as no cognitive improvement was observed in 
clinical trial (Farlow et al., 2012).   
 Further clinical testing was conducted for solanezumab by means of phase 3 
trials.  Patients over the age of 55 with a diagnosis of mild to moderate Alzheimer’s 
disease were recruited to participate in the study for 18 months (Doody et al., 2014).  
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Efficacy was determined using cognitive measurements from baseline levels established 
prior to drug administration (Doody et al., 2014).  Levels of Αβ in plasma and CSF were 
also monitored alongside MRI and PET imaging to observe amyloidogenic burden 
(Doody et al., 2014).  At 52 and 64 weeks, there were significant improvements in 
cognition observed for the solanezumab group compared to placebo; however at the 
endpoint, at 80 weeks, there were no significant group differences (Doody et al., 2014).  
Total concentrations of Αβ peptide in plasma increased from baseline over the 80 weeks 
(Doody et al., 2014).  No adverse events that affected more than 2% of the solanezumab 
group were evident, but there appeared to be a greater incidence of cardiac disease 
amongst the antibody group than placebo (Doody et al., 2014).  Imaging studies revealed 
that only 0.9% of solanezumab and 0.4% of placebo group exhibited amyloid related 
edema (Doody et al., 2014).  Though the incidence of adverse effects and amyloid 
abnormalities, edema and hemorrhage, were low for solanezumab, the phase 3 clinical 
trials did not demonstrate significant improvement in clinical outcome for the patients 
who participated (Doody et al., 2014).  
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SUMMARY 
 The experimental applications of monoclonal antibodies as well as their successes 
in targeting amyloid in vitro point to their potential in treating and possibly curing 
Alzheimer’s.  Results collectively corroborate that monoclonal antibodies to Αβ peptide 
recognize and clear amyloid species, correlating to a decline in cognitive decay in 
experiments with transgenic mice.   
 Experimentation with anti-Aβ antibodies elucidated multiple possible 
mechanisms for effectively neutralizing the toxicity of amyloid species.  Transgenic 
study by Bacskai et al. determined that administration of antibodies reduced the Aβ load 
via Fc independent phagocytosis (Bacskai et al. 2002).  The inhibition of fibrillation of 
Αβ peptide was observed by Lord et al., presenting an alternative mechanism for 
relieving Αβ burden on the brain (Lord et al. 2009).  These studies demonstrate the 
ability of antibodies to reduce, and thereby neutralize, amyloid load and toxicity.  This 
property of antibodies makes them viable options for development into Alzheimer’s 
therapeutics.   
 Clinical trials involving the active immunization with aggregated Αβ species to 
promote endogenous production of anti-Αβ antibodies proved inconclusive, as subjects 
exhibited adverse effects associated with T-cell activation (Geylis & Steinitz, 2005).  In 
subjects that succeeded in producing anti-Aβ antibodies, there was dramatic 
improvement in cognition as serum levels of antibody increased; however, not all 
subjects were able to elicit an antibody response to the vaccination of amyloid (Geylis & 
Steinitz, 2005).  To combat side effects resulting from activation of T-lymphocytes, 
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passive immunization strategies, involving vaccination with the antibodies themselves, 
were employed with early success (Geylis & Steinitz, 2005).  The various strategies 
available to administer the efficacious anti-amyloid antibodies highlight their 
developmental potential as therapeutics.  
 When compared to current treatment options for Alzheimer’s disease, monoclonal 
antibodies specifically target the pathological moieties rather than on other neurological 
aspects that are implicated by the diseases progression.  Cholinesterase inhibitors attempt 
to raise endogenous levels of acetylcholine to mediate the reduced neurotransmission 
resultant of Alzheimer’s, and memantine reduces over-activity of NMDA receptors to 
mitigate the load of reactive oxidative species.  Anti-amyloid antibodies, however, 
neutralize the toxicity of Αβ species, the precursor to the proceeding cognitive decline.  
In essence, the current treatment options address the symptoms, whereas the goal of 
antibodies is to target the source of Alzheimer’s.   
 The results of clinical trials of solanezumab and bapineuzumab demonstrate not 
only progress of antibody therapeutics, but also the obstacles that hinder such treatments 
from becoming clinically viable.  Both are humanized monoclonal antibodies to Αβ, 
developed with the hope to reverse the progression of Alzheimer’s.  Bapineuzumab 
demonstrated ability to reduce the amyloid load in the brain, but these decreases in 
amyloid levels did not exhibit a subsequent improvement cognitive ability (Rinne et al., 
2010, Salloway et al., 2014).  Additionally, bapineuzumab was associated with 
concerning adverse effects, namely amyloid-related effusion and vasogenic edema 
specific to carriers of the ApoE allele (Rinne et al., 2010).  Solaneuzumab was also 
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effective at reducing amyloid load and unlike bapineuzumab, seemingly without 
amyloid-related adverse events (Farlow et al., 2012).  However, clinical trials of 
solanezumab were unable to produce results that demonstrated improvements in 
cognition (Doody et al., 2014).  The current clinical trials with monoclonal antibodies 
have been fruitless in demonstrating their clinical efficacy in remedying cognitive 
symptoms of Alzheimer’s disease.  Though the two antibodies, solanezumab and 
bapineuzumab, have produced promising results in transgenic mice, these results have 
not been replicated in humans.  To develop antibodies into clinically useful therapeutics, 
it would be necessary to overcome the adverse effects associated with antibody, effusion 
and vasogenic edema, as well as demonstrate an ability to mediate or reverse cognitive 
decay.   
 Monoclonal antibodies demonstrate novel potential as therapeutics for the 
treatment of Alzheimer’s.  However, current strategies and antibodies have not yet 
demonstrated the same degree of success in humans as they have in transgenic mice.  To 
improve the tolerability and efficacy of monoclonal antibodies, new methods need to be 
investigated to directly deliver anti-Aβ antibodies to the central nervous system 
(Vasilevko & Cribbs, 2006).  Because the whole antibody molecule is not required for the 
clearance of amyloid species, smaller fragments of antibody (scFv) can be utilized for 
easier and more direct delivery (Vasilevko & Cribbs, 2006).  Fragments can then be 
delivered via adenovirus vectors or mesenchymal stem cells to evenly distribute antibody 
and promote uniform clearance of Aβ to optimistically produce cognitive improvement in 
Alzheimer’s patients (Vasilevko & Cribbs, 2006).  By direct delivery to the CNS, the 
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hope is that antibodies will promote activation of microglia to clear amyloid species and 
reduce neuroinflammation and subsequent cognitive loss (Vasilevko & Cribbs, 2006).     
 Differing results from clinical and transgenic mice studies question the potential 
of anti-Aβ antibodies in treating Alzheimer’s disease.  Though the successes in 
recognition and neutralization of toxic oligomeric species in transgenic mice demonstrate 
promise, the inability to replicate such results in clinical trials questions their usefulness 
as a therapeutic.  Perhaps the issue with current antibody treatments lies with the 
administration of drug.   Research demonstrates that promoting endogenous production of 
anti-amyloid antibodies to neutralize oligomers elicits positive cognitive improvements.  
The next goal of developing antibody treatments should aim to complement the human 
immune system to clear amyloid load. 
 However, there is a school of thought that the failures of antibodies to elicit 
positive clinical outcomes in the treatment of Alzheimer’s disease are evidence that the 
amyloid hypothesis itself may be flawed.  Clinical trials demonstrate that antibodies are 
effective in reducing the amyloid load in patients with no improvement in mental state or 
cognition, suggesting that amyloid itself might not be the cause of Alzheimer’s-
associated neurodegeneration (Galimberti et al. 2013).  It is suggested that research focus 
on understanding the mechanism of Alzheimer’s more thoroughly ahead of developing 
antibody therapeutics that may be ineffective (Galimberti et al. 2013).  There are some 
that consider the clinical data obtained from anti-Αβ antibody trials to be sufficient 
evidence to invalidate the entire amyloid hypothesis, so it may be necessary to ensure the 
validity of the hypothesis before moving ahead in development of treatments that address 
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amyloid burden (Mullane & Williams, 2013).   
 Despite the ability of antibodies to reduce cerebral amyloid load, and even cause 
improved cognition in transgenic mice, the implications that its inability to produce 
similar effects in clinical trials prevent antibodies from becoming viable options to 
develop into Alzheimer’s therapeutics.  The clinical outcomes that clinical trials have 
reported question the validity of the underlying amyloid hypothesis, which needs to be 
corroborated by more research before antibodies can be pursued further.  With transgenic 
mice, the antibodies show great potential, but they stumbled when moved into the clinical 
phase of testing.  However, further research needs to be conducted to determine if using 
antibodies to target amyloid load is even relevant to the treatment of the 
neurodegeneration of Alzheimer’s disease.   
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